FDA approves first treatment for acid sphingomyelinase deficiency

The U.S. Food and Drug Administration has approved Xenpozyme (olipudase alfa) for pediatric and adult patients with acid sphingomyelinase deficiency (ASMD), a rare genetic disease.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup